A systematic review posted as a preprint and indexed by Europe PMC pools the complete phase 2 and 3 trial programs for orforglipron and danuglipron, the two most clinically advanced oral small-molecule GLP-1 receptor agonists. The authors report that the two molecules diverged on regulatory fate, approval versus discontinuation, despite broadly comparable efficacy.

Both are non-peptide GLP-1 receptor agonists, meaning they act on the same target as injectable drugs like semaglutide but are built as small molecules that can be swallowed without the absorption workarounds a peptide pill requires. That is the commercial prize the whole class is chasing, and it is why a review comparing the only two programs to reach late-stage testing is worth more than either program alone.

Key results

The search returned 505 records, 286 after deduplication, of which 13 phase 2/3 randomized controlled trials met the registered criteria: 10 orforglipron, 3 danuglipron. Nine trials covering 9,693 participants entered the quantitative synthesis, with only small subsets sharing a comparator closely enough to pool.

For orforglipron, the review reports a pooled HbA1c reduction of 1.14 percentage points versus placebo (95% CI 1.25 to 1.02, I2 = 0%), plus superior glycemic control versus dapagliflozin and versus oral semaglutide. Weight change varied by population: 9.10% in obesity without diabetes from a single trial, and a pooled 6.54% in type 2 diabetes (95% CI 7.96 to 5.11, I2 = 49.8%), heterogeneity the authors attribute to background therapy.

Why danuglipron stopped

Danuglipron showed comparable glycemic and weight efficacy, according to the review, but substantially higher dose-dependent discontinuation, reaching 72.7% in one arm. Development was halted after a probable case of drug-induced liver injury in a later study that has not been published.

Against that, the authors report no hepatic safety signal across 11,220 pooled orforglipron participants. The contrast is the point of the paper: dosing regimen, tolerability and liver safety decided these two programs, not pharmacodynamic efficacy.

Limitations

This is a preprint and has not completed peer review. Only three trials could be pooled for HbA1c and two for body weight in type 2 diabetes, with the remaining estimates reported standalone, and the headline obesity weight figure rests on one trial. The critical danuglipron liver case sits in an unpublished study, so the evidence for the decision that ended that program is not itself in the public record.

Bottom line

The authors conclude that efficacy alone is an incomplete predictor of clinical success in this class. What remains unsettled is whether tolerability profiles as divergent as these are a property of individual molecules or something the oral small-molecule approach will keep producing.